BCMA CAR T-cell therapy arrives for multiple myeloma: a reality.
作者信息
Cho Shih-Feng, Anderson Kenneth C, Tai Yu-Tzu
机构信息
LeBow Institute for Myeloma Therapeutics and Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Division of Hematology & Oncology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan, China.
出版信息
Ann Transl Med. 2018 Dec;6(Suppl 2):S93. doi: 10.21037/atm.2018.11.14.
Abstract
摘要
相似文献
1
BCMA CAR T-cell therapy arrives for multiple myeloma: a reality.靶向B细胞成熟抗原的嵌合抗原受体T细胞疗法用于多发性骨髓瘤：成为现实。
Ann Transl Med. 2018 Dec;6(Suppl 2):S93. doi: 10.21037/atm.2018.11.14.
2
CAR-T Cells Based on Novel BCMA Monoclonal Antibody Block Multiple Myeloma Cell Growth.基于新型BCMA单克隆抗体的嵌合抗原受体T细胞可阻断多发性骨髓瘤细胞生长。
Cancers (Basel). 2018 Sep 11;10(9):323. doi: 10.3390/cancers10090323.
3
Anti-BCMA CAR-T cells for treatment of plasma cell dyscrasia: case report on POEMS syndrome and multiple myeloma.抗 BCMA CAR-T 细胞治疗浆细胞异常：POEMS 综合征和多发性骨髓瘤病例报告。
J Hematol Oncol. 2018 Oct 22;11(1):128. doi: 10.1186/s13045-018-0672-7.
4
Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma.BCMA 靶向 CAR-T 免疫疗法治疗多发性骨髓瘤和复发性/难治性多发性骨髓瘤概述。
Scand J Immunol. 2020 Aug;92(2):e12910. doi: 10.1111/sji.12910. Epub 2020 Jun 17.
5
A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial.复发或难治性多发性骨髓瘤患者中人性化抗CD19和抗BCMA嵌合抗原受体T细胞的联合应用：一项单臂2期试验
Lancet Haematol. 2019 Oct;6(10):e521-e529. doi: 10.1016/S2352-3026(19)30115-2. Epub 2019 Aug 1.
6
Effective Targeting of Multiple B-Cell Maturation Antigen-Expressing Hematological Malignances by Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor T Cells.嵌合抗原受体 T 细胞靶向 B 细胞成熟抗原表达的血液系统恶性肿瘤。
Hum Gene Ther. 2018 May;29(5):585-601. doi: 10.1089/hum.2018.001.
7
Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma.同种异体嵌合抗原受体 T 细胞靶向 BCMA 治疗多发性骨髓瘤的临床前评估。
Mol Ther. 2019 Jun 5;27(6):1126-1138. doi: 10.1016/j.ymthe.2019.04.001. Epub 2019 Apr 8.
8
CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.嵌合抗原受体 T 细胞增强对 B 细胞成熟抗原的敏感性，用于靶向治疗 B 细胞非霍奇金淋巴瘤和多发性骨髓瘤。
Mol Ther. 2018 Aug 1;26(8):1906-1920. doi: 10.1016/j.ymthe.2018.06.012. Epub 2018 Jun 18.
9
Idiopathic thrombocytopenic purpura treatment in a relapsed/refractory multiple myeloma patient after chimeric antigen receptor T cell therapy.嵌合抗原受体T细胞疗法后复发/难治性多发性骨髓瘤患者的特发性血小板减少性紫癜治疗
Regen Ther. 2020 May 15;14:271-274. doi: 10.1016/j.reth.2020.03.005. eCollection 2020 Jun.
10
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells.GPRC5D 是一种经理性设计的 CAR T 细胞免疫疗法的多发性骨髓瘤的靶点。
Sci Transl Med. 2019 Mar 27;11(485). doi: 10.1126/scitranslmed.aau7746.
引用本文的文献
1
BCMA-targeted therapies in multiple myeloma: advances, challenges and future prospects.多发性骨髓瘤中靶向BCMA的疗法：进展、挑战与未来前景
Med Oncol. 2025 May 8;42(6):204. doi: 10.1007/s12032-025-02753-x.
2
The Contemporary Landscape and Future Directions of Intratumoral Immunotherapy.瘤内免疫疗法的当代现状与未来方向
J Immunother Precis Oncol. 2023 Jan 17;6(2):84-90. doi: 10.36401/JIPO-22-8. eCollection 2023 May.
3
Efficacy and safety of cilta-cel in patients with progressive multiple myeloma after exposure to other BCMA-targeting agents.西达基奥仑赛治疗既往接受过其他 BCMA 靶向药物治疗的进展性多发性骨髓瘤患者的疗效和安全性。
Blood. 2023 Jan 19;141(3):219-230. doi: 10.1182/blood.2022015526.
4
Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease.人源化抗 BCMA CAR T 细胞疗法在有和无髓外疾病的复发/难治性多发性骨髓瘤患者中的疗效。
Front Immunol. 2021 Aug 5;12:720571. doi: 10.3389/fimmu.2021.720571. eCollection 2021.
5
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches.B 细胞成熟抗原（BCMA）在多发性骨髓瘤中的作用：靶向治疗的原理和当前的治疗方法。
Leukemia. 2020 Apr;34(4):985-1005. doi: 10.1038/s41375-020-0734-z. Epub 2020 Feb 13.
6
Potential factors of specialists' willingness to write editorial and commentary: a retrospective study based on 5,091 invitations.专家撰写社论和评论意愿的潜在因素：一项基于5091份邀请的回顾性研究
Ann Transl Med. 2019 Dec;7(24):805. doi: 10.21037/atm.2019.12.75.
7
An Anti-BCMA RNA Aptamer for miRNA Intracellular Delivery.一种用于miRNA细胞内递送的抗BCMA RNA适配体
Mol Ther Nucleic Acids. 2019 Dec 6;18:981-990. doi: 10.1016/j.omtn.2019.10.021. Epub 2019 Oct 28.
本文引用的文献
1
Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.靶向多发性骨髓瘤中的 B 细胞成熟抗原（BCMA）：基于 BCMA 的免疫疗法的潜在用途。
Front Immunol. 2018 Aug 10;9:1821. doi: 10.3389/fimmu.2018.01821. eCollection 2018.
2
Chimeric Antigen Receptor Therapy.嵌合抗原受体疗法
N Engl J Med. 2018 Jul 5;379(1):64-73. doi: 10.1056/NEJMra1706169.
3
T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.经基因修饰表达抗 B 细胞成熟抗原嵌合抗原受体的 T 细胞可引起预后不良的复发性多发性骨髓瘤缓解。
J Clin Oncol. 2018 Aug 1;36(22):2267-2280. doi: 10.1200/JCO.2018.77.8084. Epub 2018 May 29.
4
CAR T cell immunotherapy for human cancer.嵌合抗原受体 T 细胞免疫疗法治疗人类癌症。
Science. 2018 Mar 23;359(6382):1361-1365. doi: 10.1126/science.aar6711.
5
Elderly patients with multiple myeloma: towards a frailty approach?老年多发性骨髓瘤患者：采用衰弱评估方法？
Curr Opin Oncol. 2017 Sep;29(5):315-321. doi: 10.1097/CCO.0000000000000395.
6
CAR-Ts move beyond B-cell cancers to myeloma.嵌合抗原受体T细胞（CAR-T）疗法从B细胞癌症扩展到骨髓瘤。
Nat Biotechnol. 2017 Jul 12;35(7):599-601. doi: 10.1038/nbt0717-599.
7
Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication.破骨细胞促进多发性骨髓瘤中的免疫抑制微环境：治疗意义。
Blood. 2016 Sep 22;128(12):1590-603. doi: 10.1182/blood-2016-03-707547. Epub 2016 Jul 14.
8
T cells expressing an anti-B-cell maturation antigen chimeric antigen receptor cause remissions of multiple myeloma.表达抗B细胞成熟抗原嵌合抗原受体的T细胞可使多发性骨髓瘤缓解。
Blood. 2016 Sep 29;128(13):1688-700. doi: 10.1182/blood-2016-04-711903. Epub 2016 Jul 13.
9
APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment.APRIL和BCMA促进人多发性骨髓瘤在骨髓微环境中的生长及免疫抑制。
Blood. 2016 Jun 23;127(25):3225-36. doi: 10.1182/blood-2016-01-691162. Epub 2016 Apr 28.
10
Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy.为过继性T细胞疗法制备更优的嵌合抗原受体
Clin Cancer Res. 2016 Apr 15;22(8):1875-84. doi: 10.1158/1078-0432.CCR-15-1433.
Zotero 插件